HD 18 for advanced stages: treatment optimization trial in the first line treatment of advanced stage Hodgkin Lymphoma; treatment stratification by means of FDG-PET.

Trial Profile

HD 18 for advanced stages: treatment optimization trial in the first line treatment of advanced stage Hodgkin Lymphoma; treatment stratification by means of FDG-PET.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Rituximab (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Procarbazine; Vincristine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jun 2017 According to a media release, data was presented at the European Hematology Association (EHA) annual congress 2017.
    • 12 Feb 2017 Results of second planned interim analysis (n=1100) results published in the Lancet Oncology.
    • 17 Mar 2012 Planned end date (17 Apr 2018) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top